Overview

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Apixaban
Enoxaparin
Enoxaparin sodium
Warfarin
Criteria
Inclusion Criteria:

- Undergoing elective unilateral total knee replacement surgery.

- Willing and able to undergo bilateral ascending contrast venography.

- Able to inject (by self or caregiver) study medication subcutaneously.

Exclusion Criteria:

- Women of childbearing potential.

- Women who are pregnant or breastfeeding.

- Under some conditions, subjects weighing more than 300 lbs. (136kg) and/or Body Mass
Index (BMI) >=35 kg/m2